Skip to content

AlidaBio Unveils EpiPlex Platform for Accurate m6A and Inosine Measurement

The EpiPlex Platform from AlidaBio offers a practical solution for relative quantitation of m6A and inosine modifications. It requires minimal RNA input and can resolve subtle effects, making it a valuable tool for understanding the dynamic nature of the m6A landscape.

In front of the image there is a bottle with text, bar code and pictures on it.
In front of the image there is a bottle with text, bar code and pictures on it.

AlidaBio Unveils EpiPlex Platform for Accurate m6A and Inosine Measurement

AlidaBio has introduced the EpiPlex Platform, a tool that accurately measures N6-methyladenosine (m6A) and inosine across the transcriptome. This innovation reveals a distinct regulatory landscape and addresses limitations of current epitranscriptomics methodologies.

The EpiPlex assay combines specific enrichment of modified RNA fragments with an innovative proximity barcoding chemistry. This enables relative quantitation of multiple modifications while minimizing technical noise. The workflow can be completed in approximately seven hours, requiring only 20 ng of polyA-enriched RNA or 250 ng of total RNA.

Developed by Dr. John Smith, the platform has demonstrated its capacity to resolve subtle effects. Inhibition of METTL3 and EIF4A3 led to changes in m6A peak counts, revealing both global and region-specific changes in RNA methylation. The assay's quantitation framework includes bold enrichment, spike-in standards, and a solution control, ensuring rigor across diverse sample sets.

m6A modifications influence mRNA stability, translation, trafficking, and splicing. The EpiPlex assay was used to examine the regulation of m6A by METTL3 and EIF4A3 in HEK293T cells and to profile paired tumor/normal samples. In a matched tumor-normal liver pair from a patient with hepatocellular carcinoma, the tumor sample exhibited global hypomethylation, with both hypo- and hyper-methylation of specific transcripts observed.

The EpiPlex Platform from AlidaBio offers a practical solution for relative quantitation of m6A and inosine modifications, addressing limitations of current epitranscriptomics methodologies. Its ability to resolve subtle effects and require minimal RNA input makes it a valuable tool for understanding the dynamic nature of the m6A landscape.

Read also:

Latest